Johnson & Johnson Wound Management Worldwide Introduces ACTISORB* Silver 220 Antimicrobial Binding Dressing to the U.S.

Triple-Action System Attacks Bacteria, Binds Toxins and Stops Odor

SOMERVILLE, N.J., Mar 25, 2003 /PRNewswire-FirstCall via COMTEX/ --

Johnson & Johnson Wound Management today announced the introduction of ACTISORB* Silver 220 Antimicrobial Binding Dressing, the first and only primary wound dressing in the United States that combines broad-spectrum antimicrobial action, bacterial toxin management and odor control.

ACTISORB Silver 220 dressing has been proven effective in vitro against more than 150 clinically relevant wound pathogens, including antibiotic resistant strains such as Staphylococcus aureus and Vancomycin-resistant Enterococcus.(1) As seen in clinical studies of more than 12,400 chronic wounds, the dressing has a proven history of safety and effectiveness.(2)

In a recently published paper, it was concluded that ACTISORB Silver 220 dressing may be beneficial in the treatment of infected wounds, particularly when colonized by Gram-negative bacteria. The dressing demonstrated a high in vitro endotoxin-binding capacity combined with marked bactericidal activity without releasing Pseudomonas aeruginosa endotoxins into the environment.(3)

Chronic wounds are growing in frequency due to the advancing age of the population and improved diagnosis and education. Each year there are more than 19 million venous, pressure and diabetic ulcers worldwide that require treatment. Infection at the wound site is a significant complication of the wound repair.(4)

ACTISORB Silver 220 dressing provides an effective barrier to bacterial penetration and adsorbs offending odor resulting from wounds; the binding properties of the dressing trap bacteria, bacterial toxins and odor. ACTISORB Silver 220 dressing may help reduce infection in partial- and full-thickness wounds, including pressure ulcers, venous ulcers, diabetic ulcers, first- and second-degree burns, donor sites and surgical wounds. It is suitable for use under compression bandaging.

ACTISORB Silver 220 dressing should not be used on third-degree burns or on patients with known sensitivity to silver. For more information, visit www.actisorbsilver.com.

Johnson & Johnson Wound Management, a division of ETHICON, INC., a Johnson & Johnson company, continues Johnson & Johnson's 100-year commitment to skin and wound care today with inventive products for chronic and acute wound management, burn care and hemostasis. For more information about Johnson & Johnson Wound Management or other ETHICON divisions, call 877-384-4266 in the United States or visit www.jnjgateway.com or www.ethiconinc.com.

*Trademark

(1) Data on File
(2) "Treatment of chronic wounds with ACTISORB* - Overview of five observational studies including 12,444 documented cases", presented by R. Stadler, May 2002.

SOURCE ETHICON, INC.

Amy Firsching of ETHICON, INC., +1-908-218-2783, afirschi@ethus.jnj.com

http://www.actisorbsilver.com

Copyright (C) 2003 PR Newswire. All rights reserved.